Neurosurgical Perspectives on NF1-Associated Tumors: Augmenting Surgical Approaches with Targeted Medical Therapies
This educational activity is targeted to pediatric neurosurgeons, neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, pediatric hem/onc nurses, and other members of the interprofessional, multidisciplinary neuro-oncology team attending the 2021 AANS/CNS section on Pediatric Neurological Surgery who care for patients with neurofibromatosis type 1 (NF1). Designed and developed to provide an interactive overview of novel and emerging data, as well as establish a foundational context of NF1 disease state complexity, this symposium will conclude with a dynamic case-based approach, elucidating the role of the neurosurgeon in augmenting and optimizing surgical strategies through the integration of MEK inhibitors into NF1 treatment strategies.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
At the conclusion of this live activity, participants will gain the skills and/or knowledge to:
- Review recently-updated NF1 diagnostic criteria and recognize established NF1 clinical manifestations to promote earlier detection and treatment initiation, especially in pediatric patients.
- Describe the complex physical and pathophysiologic features of NF1-related plexiform neurofibromas that make them difficult to manage surgically.
- Evaluate the shortcomings of traditional NF1-associated plexiform neurofibroma treatment modalities, including surgery and radiation, and emphasize how targeted therapies like MEK inhibitors are poised to improve outcomes.
- Appraise completed and ongoing clinical trial data for novel targeted therapies being studied as non-surgical alternatives in NF1-associated tumors, with an emphasis on current expert consensus recommendations and FDA-approved indications.
- Identify the critical role(s) of the neurosurgeon on the multidisciplinary NF1 treatment team, and design practical, evidence-based treatment plans using MEK inhibitors for management of NF1-associated tumors.
10 minutes Welcome and Introductions/Pre-test
15 minutes The NF1 Essentials: Multisystem Pathophysiology, Revised Diagnostic Criteria, & Inoperable Plexiforms
25 minutes The Revolution: Exploring the Expanding Evidentiary Base for Targeted Therapies in NF1-Associated Tumors
30 minutes The Real World: Practical MEK Inhibitor Strategies for the Neurosurgeon in a Shifting Therapeutic Landscape
10 minutes Conversations with the Experts: Audience Q&A/Post-test
Miriam Bornhorst, MD
Gilbert Neurofibromatosis Institute
Children’s National Hospital
Miriam Bornhorst is the Clinical Director of the Gilbert Neurofibromatosis Institute and Medical Director of the Cancer Genetics Clinic at Children’s National Hospital (CNH) in Washington, DC. She also has a joint appointment as an Assistant Professor in Pediatrics at George Washington University Hospital. After receiving her Medical Degree from Creighton University, Dr. Bornhorst completed pediatric residency and Pediatric Hematology/Oncology fellowship at the University of Michigan followed by Neuro-oncology fellowship training at CNH. Her main clinical interests are cancer predisposition, neurofibromatosis type 1, and neuro-oncology. Her research focuses on the early detection and treatment of patients at risk for developing cancer, including biomarker discovery, and metabolism in NF1.
Holly S. Gilmer, MD
Michigan Head & Spine Institute
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Miriam Bornhorst, MD–has disclosed that she is a consultant for AstraZeneca.
Holly S. Gilmer, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Reviewer to come.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a post-test and evaluation, statements of credit for physicians will be issued within 30 business days.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation